<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05032690</url>
  </required_header>
  <id_info>
    <org_study_id>B1871062</org_study_id>
    <secondary_id>2021-004911-24</secondary_id>
    <nct_id>NCT05032690</nct_id>
  </id_info>
  <brief_title>Evaluation of the Relative Bioavailability of Bosutinib Capsules Under Fed Condition and Estimation of Food Effect on Orally Administered Bosutinib Capsule</brief_title>
  <official_title>A PHASE 1, RANDOMIZED, OPEN-LABEL, 3-PERIOD, 4-SEQUENCE, CROSSOVER, SINGLE-DOSE STUDY TO COMPARE THE BIOAVAILABILITY OF ORALLY ADMINISTERED BOSUTINIB CAPSULES AND TO ESTIMATE THE EFFECT OF FOOD ON BOSUTINIB CAPSULE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to estimate the bioavailability of a single 100 mg bosutinib capsules&#xD;
      relative to four 25 mg capsules under fed condition in adult healthy participants and to&#xD;
      estimate the effect of a high-fat, high-calorie meal on the bioavailability of a single 100&#xD;
      mg capsule of bosutinib relative to fasted condition in adults healthy participants. The&#xD;
      comparisons will be performed using the pharmacokinetic parameters that define the rate and&#xD;
      extend of absorption (Cmax, AUC). Statistical analyses will be performed after the&#xD;
      administration of a single 100 mg dose under fed condition as the Reference treatment and the&#xD;
      four 25 mg capsules as the Test treatment for the first comparison, and after administration&#xD;
      of a single 100 mg dose under fasted condition as the Reference treatment and the 100 mg&#xD;
      capsule under fed condition as the Test treatment for the second comparison.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 19, 2022</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>A Phase 1, open-label, randomized, single dose, 3-period, 4 sequence, crossover study in healthy participants</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-inf)]</measure>
    <time_frame>6 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>6 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)</measure>
    <time_frame>6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax)</measure>
    <time_frame>6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Clearance (CL/F)</measure>
    <time_frame>6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F)</measure>
    <time_frame>6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma elimination half-life (t1/2)</measure>
    <time_frame>6 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Treatment B: Bosutinib four 25 mg capsule after meal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bosutinib four 25 mg capsule taken after a high-fat and high-calorie breakfast for comparison 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment A: Bosutinib 100 mg capsule after meal (active comparator)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bosutinib 100 mg capsule taken after a high-fat and high-calorie breakfast for comparison 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment A: Bosutinib 100 mg capsule after meal (experimental)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bosutinib 100 mg capsule taken after a high-fat and high-calorie breakfast for comparison 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C: Bosutinib 100 mg capsule after fasting</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bosutinib 100 mg capsule taken after an overnight fast of at least 10 hours for comparison 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosutinib capsule</intervention_name>
    <description>Bosutinib four 25 mg capsule taken after a high-fat and high calorie breakfast</description>
    <arm_group_label>Treatment B: Bosutinib four 25 mg capsule after meal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosutinib capsule</intervention_name>
    <description>Bosutinib 100 mg capsule taken after a high-fat and high calorie breakfast</description>
    <arm_group_label>Treatment A: Bosutinib 100 mg capsule after meal (active comparator)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosutinib</intervention_name>
    <description>Bosutinib 100 mg capsule taken after an overnight fast of at least 10 hours</description>
    <arm_group_label>Treatment C: Bosutinib 100 mg capsule after fasting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosutinib capsule</intervention_name>
    <description>Bosutinib 100 mg capsule taken after a high-fat and high-calorie breakfast</description>
    <arm_group_label>Treatment A: Bosutinib 100 mg capsule after meal (experimental)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female participants of non-childbearing potential and/or male participants must be 18&#xD;
             to 55 years of age, inclusive, at the time of signing the informed consent document&#xD;
             (ICD)&#xD;
&#xD;
          -  participants who are overtly healthy as determined by medical evaluation including a&#xD;
             detailed medical history, complete physical examination, vital signs which include BP&#xD;
             and pulse rate measurement, clinical laboratory tests, and electrocardiogram (ECG).&#xD;
&#xD;
          -  Participants who are willing and able to comply with all scheduled visits, treatment&#xD;
             plan, laboratory tests, lifestyle considerations, and other study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence or history of clinically significant hematological, renal, endocrine,&#xD;
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological,&#xD;
             dermatological, or allergic disease.&#xD;
&#xD;
          -  Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).&#xD;
&#xD;
          -  History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C;&#xD;
             positive testing for HIV, HBsAg,hepatitis B surface antigen (HBcAb) or hepatitis C&#xD;
             antibody (HCVAb).&#xD;
&#xD;
          -  Participants with ANY of the following abnormalities in clinical laboratory tests at&#xD;
             screening, as assessed by the study-specific laboratory and confirmed by a single&#xD;
             repeat test, if deemed necessary:&#xD;
&#xD;
               -  estimated glomerular filtration rate (eGFR) (Chronic Kidney Disease Epidemiology&#xD;
                  Collaboration [CKD-EPI]) &lt;90 mL/min/1.73 m2;&#xD;
&#xD;
               -  aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level &gt;upper&#xD;
                  limit of normal (ULN);&#xD;
&#xD;
               -  Serum (total and direct) bilirubin level &gt; ULN; participants with a history of&#xD;
                  Gilbert's syndrome may have direct bilirubin measured and would be eligible for&#xD;
                  this study provided the direct bilirubin level is &lt;= ULN;&#xD;
&#xD;
               -  Amylase and lipase level &gt; ULN.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pfizer Clinical Research Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B1871062</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioavailability</keyword>
  <keyword>Food Effect</keyword>
  <keyword>Bosutinib</keyword>
  <keyword>Maximum Observed Plasma Concentration (Cmax)</keyword>
  <keyword>Area Under the Curve (AUC)</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

